Department of Gastroenterology, Weifang People's Hospital, China.
Infectious Diseases Department, Weifang People's Hospital, China.
J Int Med Res. 2021 Sep;49(9):3000605211041466. doi: 10.1177/03000605211041466.
This study explored the functional interactions between the long non-coding RNA DICER-AS1 and the cellular stress response 1 () gene in gastric cancer.
Quantitative polymerase chain reaction (qPCR) and western blotting were used to measure DICER-AS1, CSR1, and miR-650 expression levels. Gastric cancer cell line proliferation and migration abilities were analyzed using the MTT and transwell migration and invasion assays, respectively. Bioinformatic analysis and dual luciferase reporter assays were employed to study the functional interactions among miR-650, DICER-AS1, and .
DICER-AS1 and expression levels were significantly decreased in gastric cancer tissues compared with normal tissues, and qPCR analysis showed that miR-650 was upregulated in gastric cancer tissues. Bioinformatic analysis and dual luciferase reporter assays revealed that DICER-AS1 functioned as a competing endogenous RNA that sponged miR-650, which in turn regulated expression. Importantly, ectopic DICER-AS1 and expression inhibited cell proliferation and migration and suppressed xenograft tumorgenicity .
These results suggest that DICER-AS1 functions as a competing endogenous RNA that regulates miR-650 to suppress proliferation and migration of gastric cancer cells by targeting . These findings indicate that targeting DICER-AS1 and miR-650 could be a novel treatment for gastric cancer.
本研究探讨了长链非编码 RNA DICER-AS1 与细胞应激反应 1 () 基因在胃癌中的功能相互作用。
采用定量聚合酶链反应(qPCR)和 Western blot 检测 DICER-AS1、CSR1 和 miR-650 的表达水平。采用 MTT 和 Transwell 迁移和侵袭实验分析胃癌细胞系的增殖和迁移能力。通过生物信息学分析和双荧光素酶报告基因实验研究 miR-650、DICER-AS1 和 之间的功能相互作用。
与正常组织相比,胃癌组织中 DICER-AS1 和 表达水平显著降低,qPCR 分析显示胃癌组织中 miR-650 表达上调。生物信息学分析和双荧光素酶报告基因实验表明,DICER-AS1 作为竞争性内源性 RNA 发挥作用,可吸附 miR-650,进而调节 表达。重要的是,外源性 DICER-AS1 和 表达抑制细胞增殖和迁移,并抑制异种移植肿瘤生成能力。
这些结果表明,DICER-AS1 作为竞争性内源性 RNA 通过靶向 调节 miR-650 抑制胃癌细胞的增殖和迁移。这些发现表明,靶向 DICER-AS1 和 miR-650 可能为胃癌提供一种新的治疗方法。